Kazia Therapeuti Stock Price, News & Analysis

Kazia Therapeutics Limited (NASDAQ: KZIA) will present at the HC Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. CEO Dr. James Garner will discuss the company's pivotal study on paxalisib, aimed at treating glioblastoma, which affects over 12,500 patients annually. The market potential for this treatment is valued at US$ 1.5 billion. Significant developments include an out-licensing deal for pazalisib in Greater China and in-licensing of another oncology asset, EVT801. Dr. Garner will also outline Kazia's objectives for FY2022.

Kazia Therapeutics Limited (NASDAQ: KZIA) highlights Glioblastoma (GBM) Awareness Day on July 21, 2021, urging increased research focus on this aggressive brain cancer, which affects around 13,000 Americans annually. Current GBM treatments yield limited benefits, with median survival at 16 months. CEO Dr. James Garner expresses confidence in future treatment advancements, particularly with the drug paxalisib, currently in phase II trials. Kazia calls for collaboration among stakeholders to improve GBM treatment prospects.

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) provided an update on its oncology pipeline, focusing on paxalisib and EVT801. The GBM AGILE study for paxalisib is recruiting nearly 25 sites ahead of schedule in the U.S., with over 650 patients screened to date. The phase II study of paxalisib has seen its final patient complete treatment, while the phase I study of EVT801 has submitted its protocol to French regulators. Kazia anticipates upcoming data releases from ongoing studies in 2021.

Kazia Therapeutics Limited (NASDAQ: KZIA) has initiated a collaboration with Weill Cornell Medical College for a Phase II clinical trial examining paxalisib combined with a ketogenic diet for glioblastoma treatment. This study aims to explore the potential of ketogenesis in enhancing paxalisib's effectiveness and reducing side effects like hyperglycemia. Led by Dr. Howard Fine, the trial will consist of two arms, with an initial cohort of 16 patients in each. Recruitment is expected to start by the end of 2021, pending regulatory approvals.

Kazia Therapeutics Limited (NASDAQ: KZIA) has initiated a phase II clinical study of its investigational drug, paxalisib, targeting primary CNS lymphoma at the Dana-Farber Cancer Institute. The study, which has enrolled its first patient, aims to recruit a total of 25 patients over the next two years. Paxalisib is the only PI3K inhibitor capable of penetrating the blood-brain barrier, addressing a significant treatment gap for patients with CNS lymphoma. Kazia is providing support for the trial, including the study drug and financial grant.

Kazia Therapeutics Limited (NASDAQ: KZIA) announced that its CEO, Dr. James Garner, will present virtually at the LD Micro Invitational XI on June 9, 2021, at 5 PM ET. The company is advancing its lead program, paxalisib, in a pivotal study for glioblastoma and expects to begin clinical trials for a new program, EVT801, in 2021. The LD Micro Invitational runs from June 8-10, showcasing around 180 companies. Investors can register for free at the event's website.

Kazia Therapeutics has expanded its pipeline by acquiring EVT801, a small molecule inhibitor targeting VEGFR3, from Evotec for €1m upfront plus potential milestones of €308m and tiered single-digit royalties. EVT801, developed in collaboration with Sanofi, is currently in preclinical development, with a Phase I study expected to launch by the end of CY21. The company increased its valuation to US$247m or US$19.14 per basic ADR, up from US$215m. This expansion also raises Kazia's financing requirement to US$36m from US$7m, reflecting increased R&D spending.

Kazia Therapeutics has entered a worldwide exclusive licensing agreement with Evotec SE for EVT801, a first-in-class oncology drug candidate. Kazia will pay €1 million upfront and up to €308 million in contingent milestones. EVT801, a small-molecule VEGFR3 inhibitor, targets lymphangiogenesis to combat tumor growth and may enhance immuno-oncology therapies. The phase I clinical trial is expected to launch in 2021, focusing on cancers such as renal cell carcinoma and hepatocellular carcinoma. This collaboration aims to expedite EVT801's development.

Kazia (NASDAQ:KZIA) has secured an agreement with Simcere Pharmaceuticals for the Greater China rights to paxalisib. The deal entails an upfront payment of US$11 million, comprising US$7 million in cash and US$4 million in equity. Additionally, the agreement includes up to US$281 million in milestone payments and mid-teen royalties. This strategic move reduces Kazia's expected financing needs from US$14 million to US$7 million and increases the company's valuation to US$215 million, or US$16.60 per basic ADR.